CROI 2018: third reports
16 April 2018. Related: Conference reports.
CROI 25 (Retrovirus) 2018
No increased risk of IRIS in people with low CD4 counts receiving raltegravir in the REALITY trial
16 April 2018. Related: Conference reports, Coinfections and complications.
Isoniazid preventive TB therapy in pregnancy and postpartum: recommendations now need to be re-evaluated
16 April 2018. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
Efavirenz might decrease effectiveness of the vaginal contraceptive ring
16 April 2018. Related: Conference reports, Pregnancy, PK and drug interactions.
Switch to TAF appears safe and effective in adolescents: similar PK to adults
16 April 2018. Related: Conference reports, Paediatric care.
Doubling raltegravir dose could overcome interaction with rifampicin in children aged 2 to 6
16 April 2018. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
Reducing risk of myocardial infarction (MI) in HIV positive people
16 April 2018. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
M184V mutation associated with increased risk of viral blip but not viral failure with 3TC-based dual therapy
16 April 2018. Related: Conference reports, Treatment strategies, Drug resistance.
CROI 2018: second reports
30 March 2018. Related: Conference reports.
Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV
30 March 2018. Related: Conference reports, Antiretrovirals.
Statin use might reduce risk of cancer in HIV positive people
30 March 2018. Related: Conference reports, Cancer and HIV.
Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study
30 March 2018. Related: Conference reports, Pregnancy.
Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum
30 March 2018. Related: Conference reports.
25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)
14 March 2018. Related: Conference reports.
Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques
14 March 2018. Related: Conference reports, Cure-related research.
No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification
14 March 2018. Related: Conference reports, Cure-related research.
Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment
14 March 2018. Related: Conference reports, TB coinfection.
Twice-daily dolutegravir is effective and tolerable with rifampicin
14 March 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin
14 March 2018. Related: Conference reports, TB coinfection.
Bictegravir at CROI 2018: switching studies and drug resistance analyses
14 March 2018. Related: Conference reports, Antiretrovirals, Drug resistance.
PrEP at CROI 2018 (part 1): Access in Australia and the US
14 March 2018. Related: Conference reports, HIV prevention and transmission.
PrEP at CROI 2018 (part 2): Animal studies for future drugs
14 March 2018. Related: Conference reports, HIV prevention and transmission.
BHIVA best of CROI feedback workshops
14 March 2018. Related: Conference reports.
CROI 2018 – highlights from the preliminary programme
23 February 2018. Related: Conference reports.